# Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act

Source: https://onco.cc/trials/nct07829549/  
OnCo record `nct07829549` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of carboplatin and tislelizumab in lung cancer, run by RemeGen Co., Ltd., not yet recruiting.

## Summary

Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations is a phase 3, randomised interventional study registered as NCT07829549 by RemeGen Co., Ltd., with a registry enrolment figure of 540 participants, started 2026-09-30 and due to reach its primary completion in 2031-04. Interventions recorded: RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection; Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection. Conditions listed: Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations. Primary outcome: Progression-Free Survival assessed by BIRC per RECIST v1.1. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced or metastatic NSCLC, not amenable to curative-intent therapy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07829549
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase III Study of RC148 Combined With Platinum-Based Chemotherapy Versus Tislelizumab Combined With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 540

## Sources

- ClinicalTrials.gov NCT07829549: https://clinicaltrials.gov/study/NCT07829549

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07829549.json